Compositions and methods comprising glycyl-tRNA synthetases having non-canonical biological activities
AssigneeaTyr Pharma, Inc.
InventorsLeslie Ann Greene, Ryan Andrew Adams, Fei Hong, Ji Zhao, Eva Rebecka Stephanie Armour, Kristi Helen Piehl
Life of this patent
Estimating the term…
Abstract
Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
Claims12
A method for treating a condition comprising administering to a subject in need thereof a therapeutic composition, comprising a pharmaceutically-acceptable carrier and an isolated glycyl-tRNA synthetase (GRS) polypeptide selected from (a) a polypeptide that comprises SEQ ID NO:1, (b) a fragment of (a) comprising at least 600 contiguous amino acids of SEQ ID NO:1, and (c) a variant of (a) having at least 95% identity to SEQ ID NO:1, where the GRS polypeptide has cell signaling activity and is at least about 90% pure, where the composition is sterile and pyrogen-free, and where the condition is selected from the group consisting of inflammatory diseases, autoimmune diseases, neoplastic diseases, metabolic diseases, neurological diseases, infections, cardiovascular diseases, and diseases associated with abnormal angiogenesis.
A method for modulating a cellular activity comprising contacting a cell or tissue with a therapeutic composition, comprising a pharmaceutically-acceptable carrier and an isolated glycyl-tRNA synthetase (GRS) polypeptide selected from (a) a polypeptide that comprises SEQ ID NO:1, (b) a fragment of (a) comprising at least 600 contiguous amino acids of SEQ ID NO:1, and (c) a variant of (a) having at least 95% identity to SEQ ID NO:1, where the GRS polypeptide has cell signaling activity and is at least about 90% pure, and where the composition is sterile and pyrogen-free.
Dependencies are inferred from the claim text.